norfloxacin has been researched along with Agranulocytosis in 17 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 9.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 9.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group." | 6.66 | Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 6.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 5.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 5.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "or t." | 3.76 | World-wide clinical experience with norfloxacin: efficacy and safety. ( Corrado, M; Hoagland, V; Sabbaj, J; Wang, C, 1986) |
| "To prevent bacterial infections in the neutropenic post-transplant period, norfloxacin 400mg twice daily was administered as oral prophylaxis to 44 marrow recipients isolated in laminar airflow rooms (LAFRs)." | 3.67 | Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. ( Aversa, F; Bucaneve, G; Del Favero, A; Felicini, R; Greco, M; Martelli, MF; Menichetti, F; Moretti, MV; Pasquarella, C, 1989) |
| "Selective antimicrobial decontamination with norfloxacin was compared with vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients." | 3.67 | Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. ( Champlin, RE; Gale, RP; Ho, WG; Nakao, SL; Winston, DJ, 1986) |
| " We have previously demonstrated that the ability to suppress bacterial colonization of this site with oral norfloxacin prophylaxis (400 mg every 12 h) affects the incidence and distribution of aerobic gram-negative bacterial infections and the overall management of infectious complications in this patient population." | 3.67 | Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient. ( Dick, JD; Karp, JE; Merz, WG, 1988) |
| "Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group." | 2.66 | Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988) |
| "Norfloxacin has been compared to placebo (136 patients), sulfamethoxazole plus trimethoprim (SXT, 72 patients) and oral vancomycin plus colistin (V/C, 61 patients) for the prevention of alimentary tract-associated infections during and after induction chemotherapy." | 2.66 | The tolerability profile of prophylactic norfloxacin in neutropenic patients. ( Corrado, ML; Hesney, M; Struble, WE, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 2.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liso, V | 1 |
| Specchia, G | 1 |
| Pavone, V | 1 |
| Pansini, N | 1 |
| Capalbo, S | 1 |
| Ostuni, A | 1 |
| Mastria, A | 1 |
| Colucci, A | 1 |
| Costantino, G | 1 |
| Urquia, A | 1 |
| Ziad, F | 1 |
| Serrano, R | 1 |
| Lacasa, J | 1 |
| Llinares, F | 1 |
| Del Favero, A | 3 |
| Martino, P | 1 |
| Bucaneve, G | 3 |
| Micozzi, A | 1 |
| D'Antonio, D | 1 |
| Minetti, B | 1 |
| Ricci, P | 1 |
| Landonio, G | 1 |
| Montillo, M | 1 |
| Malleo, C | 1 |
| Murray, BE | 1 |
| Nemet, D | 1 |
| Kalenic, S | 1 |
| Badanjak, A | 1 |
| Bogdanic, V | 1 |
| Davila, N | 1 |
| Francetić, I | 1 |
| Labar, B | 1 |
| Menichetti, F | 2 |
| Felicini, R | 1 |
| Aversa, F | 1 |
| Greco, M | 1 |
| Pasquarella, C | 1 |
| Moretti, MV | 1 |
| Martelli, MF | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Winston, DJ | 2 |
| Ho, WG | 2 |
| Nakao, SL | 1 |
| Gale, RP | 1 |
| Champlin, RE | 2 |
| Karp, J | 1 |
| Bartlett, J | 1 |
| Finley, RS | 1 |
| Joshi, JH | 1 |
| Talbot, G | 1 |
| Levitt, L | 1 |
| Deresinski, S | 1 |
| Schmeiser, T | 1 |
| Kurrle, E | 1 |
| Arnold, R | 1 |
| Wiesneth, M | 1 |
| Bunjes, D | 1 |
| Hertenstein, B | 1 |
| Kern, W | 1 |
| Heit, W | 1 |
| Heimpel, H | 1 |
| Casali, A | 1 |
| Verri, C | 1 |
| Paoletti, G | 1 |
| Tropea, F | 1 |
| Modugno, G | 1 |
| Frasca, AM | 1 |
| Ameglio, F | 1 |
| Tonachella, R | 1 |
| Gallo Curcio, C | 1 |
| Karp, JE | 3 |
| Dick, JD | 1 |
| Merz, WG | 3 |
| Corrado, ML | 1 |
| Struble, WE | 1 |
| Hesney, M | 1 |
| Hendricksen, C | 2 |
| Laughon, B | 2 |
| Redden, T | 2 |
| Bamberger, BJ | 2 |
| Bartlett, JG | 2 |
| Saral, R | 2 |
| Burke, PJ | 2 |
| Wang, C | 1 |
| Sabbaj, J | 1 |
| Corrado, M | 1 |
| Hoagland, V | 1 |
| Patoia, L | 1 |
| Guerciolini, R | 1 |
2 reviews available for norfloxacin and Agranulocytosis
| Article | Year |
|---|---|
Quinolones and the gastrointestinal tract.
Topics: Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Biliary Tract Diseases; Diarrhea; Drug | 1989 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
9 trials available for norfloxacin and Agranulocytosis
| Article | Year |
|---|---|
[Prophylaxis using quinolones in neutropenic patients. Preliminary results of a cooperative study by the Grupo Italiano Malattie Ematologiche maligne dell'adulto (GIMEMEA)].
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Bone Marrow Transplantation; Ciproflox | 1989 |
Prevention of gram-negative bacterial infection in granulocytopenic patients: a randomized study comparing oral norfloxacin with gentamycin.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Bacterial Infections; Gentamicins; Gram-Ne | 1989 |
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Combinations; Drug Therapy, Com | 1987 |
Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Humans; Neoplasms; | 1988 |
The tolerability profile of prophylactic norfloxacin in neutropenic patients.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Colistin; Diarrhea; Gastrointestina | 1988 |
Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Agranulocytosis; Bacterial Infections; Clinical Tr | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents | 1987 |
7 other studies available for norfloxacin and Agranulocytosis
| Article | Year |
|---|---|
Prophylactic administration of oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemias.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents | 1989 |
[Agranulocytosis caused by norfloxacin].
Topics: Aged; Agranulocytosis; Humans; Male; Norfloxacin | 1989 |
Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Child; Enviro | 1989 |
Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Evaluation; Drug Tolerance; Fem | 1986 |
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Female; Human | 1988 |
Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.
Topics: Administration, Oral; Agranulocytosis; Bacterial Infections; Digestive System; Gastrointestinal Dise | 1988 |
Norfloxacin and neutropenia.
Topics: Adult; Agranulocytosis; Female; Humans; Neutropenia; Norfloxacin | 1987 |